Cellebrite DI (NASDAQ:CLBT – Get Rating) had its price objective increased by stock analysts at Needham & Company LLC from $6.50 to $7.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s target price suggests a potential upside of 21.42% from the company’s current price.
Separately, TheStreet raised Cellebrite DI from a “d+” rating to a “c-” rating in a research report on Friday, February 3rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Cellebrite DI has a consensus rating of “Moderate Buy” and an average price target of $8.60.
Cellebrite DI Price Performance
Shares of CLBT stock opened at $5.77 on Tuesday. The stock has a market cap of $1.09 billion, a P/E ratio of 9.45, a price-to-earnings-growth ratio of 1.00 and a beta of 1.19. Cellebrite DI has a one year low of $3.80 and a one year high of $7.63. The stock has a fifty day moving average price of $5.33 and a 200 day moving average price of $4.77.
Institutional Inflows and Outflows
Cellebrite DI Company Profile
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.
- Get a free copy of the StockNews.com research report on Cellebrite DI (CLBT)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.